Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome

Blood

Volumn 87, Issue 4, 1996, Pages 1458-1465

  Gherardi, Romain K ^a   Bélec, Laurent ^b   Soubrier, Martin ^b   Malapert, Denis ^b   Zuber, Mathieu ^b   Viard, Jean Paul ^b   Intrator, Liliane ^b   Degos, Jean Denis ^b   Authier, François Jérôme ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; M PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ACTIVITY; ENDOCRINE DISEASE; FEMALE; HEPATOSPLENOMEGALY; HUMAN; INFLAMMATION; MALE; MULTIPLE MYELOMA; PARAPROTEINEMIA; POLYNEUROPATHY; PRIORITY JOURNAL; SKIN DISEASE; THROMBOCYTE COUNT;

EID: 0030022090     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.4.1458.bloodjournal8741458     Document Type: Article

References (55)

1. Bardwick PA, Zwaifler NJ, Gill GN, Newman D, Greenway GD: Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes: The POEMS syndrome, Medicine 59:311, 1980
2. Nakanishi T, Sobue I, Toyokura Y, Nishitani H, Kuroiwa Y, Satoyoshi E, Tsubaki T, Igata A, Ozaki Y: The Crow-Fukase syndrome: A study of 102 cases in Japan. Neurology 34:712, 1984
3. Miralles GD, O'Fallon JR, Talley NJ: Plasma cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med 327:1919, 1992
4. Gherardi R, Zuber M, Viard JP: Les neuropathies dysglobulinémiques. Rev Neurol (Paris) 144:391, 1988
5. Fukatsu A, Ito Y, Yuzawa Y, Yoshida F, Kato M, Miyakawa K, Matsuo S: A case of POEMS syndrome showing elevated serum interleukin 6 and abnormal expression of interleukin 6 in the kidney. Nephron 62:47, 1992
6. Mandler RN, Kerrigan DP, Smart J, Kuis W, Villiger P, Lotz M: Castleman's disease in POEMS syndrome with elevated interleukin-6. Cancer 69:2697, 1992
7. Gherardi RK, Belec L, Fromont G, Divine M, Malapert D, Gaulard P, Degos J-D: Elevated levels of IL-1β and IL-6 in serum, and increased production of IL-1β mRNA in lymph nodes of patients with POEMS syndrome. Blood 83:2587, 1994
8. Emile C, Danon F, Fermand JP, Clauvel JP: Castleman disease in POEMS syndrome with elevated interleukin-6 Cancer 71:874, 1993 (letter)
9. Gherardi RK, Chouaïb S, Malapert D, Belec L, Intrator L, Degos JD: Early weight loss and high serum levels of tumor necrosis factor-α in patients with POEMS syndrome. Ann Neurol 35:501, 1994
10. Sharief MK, McLean B, Thomson EJ: Elevated serum levels of tumor necrosis factor-α in Guillain-Barre syndrome. Ann Neurol 333:591, 1991
11. Créange A, Bélec L, Clair B, Raphael JC, Gherardi RK: Differential kinetics of circulating tumor necrosis factor (TNF)-alpha and soluble TNF receptors (sTNFrs) in patients with Guillain-Barré syndrome (GBS). Neurology 45.A415, 1995 (suppl 4)
12. Varesio L, Espinoza-Delgado I, Gusella L, Cox GW, Melillo G, Musso T, Bosco MC: Role of cytokines in the activation of monocytes, in Aggarwal BB, Puri RK (eds): Human Cytokines: Their Role in Disease and Therapy. Cambridge, MA, Blackwell Science, 1995, p 55
13. te Velde AA, Huijbens RJF, Heije K, de Vries JE, Figdor CG: Interleukin 4 (IL-4) inhibits secretion of IL-1β, tumor necrosis factor-α and IL-6 by human monocytes. Blood 76:1392, 1990
14. de Malefyt RW, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209, 1991
15. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatois P, Lauzun P, Miloux B, Minty C, Casellas P, Loison G, Lupker J, Shire D, Ferrara P, Caput D: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362:248, 1988
16. Legres LG, Pochon F, Barray M, Heinrich PC, Delain E: Human alpha 2-macroglobulin as a cytokine-binding plasma protein. A study with rh-interjeukin 1beta and rh-interleukin 6. Ann NY Acad Sci 737:439, 1994
17. Seckinger P, Isaaz S, Dayer J-M: A human inhibitor of tumor necrosis factor-α. J Exp Med 167:1511, 1988
18. Engelmann H, Novick D, Wallach D: Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265:1531, 1990
19. Lantz M, Malik S, Slevin ML, Olsson I: Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2:402, 1990
20. Aderka D, Engelmann H, Maor Y, Brakbusch C, Wallach D: Stabilization of the bioactivity of tumour necrosis factor by its soluble receptors. J Exp Med 175:323, 1992
21. Burger D, Chicheportiche R, Giri JG, Dayer JM: The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukine 1 soluble receptor. J Clin Invest 96:38, 1995
22. Salvati AL, Lahm A, Paonessa G, Ciliberto G, Toniatti C: Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor alpha mutated in the predicted gp130-binding surface. J Biol Chem 270:12242, 1995
23. Roberts AB, Sporn MB: Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 8:1, 1993
24. Kulkarni AB, Karlsson S: Transforming growth factor-β knockout mice. Am J Pathol 143:3, 1993
25. Viard JP, Lesavre P, Boitard C, Noel LH, Roth A, Said G, Bach JF: POEMS syndrome presenting as systemic sclerosis: Clinical and pathological study of a case with microangiopathic glomerular lesions. Am J Med 84:524, 1988
26. Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, Smith BE, Kratz KM, Karnes JL, Evans BA, Pineda AA, O'Brien P, Kyle RA: Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 325:1482, 1991
27. Akira S, Hirano T, Taga T, Kishimoto T: Biology of multifunctional cytokines: IL6 and related molecules (IL1 and TNF). FASEB J 4:2860, 1990
28. Gherardi RK, Amiel H, Martin-Mondiere C, Viard JP, Salama J, Delaporte P: Solitary plasmocytoma of the skull revealed by a mononeuritis multiplex associated with immune complex vasculitis. Arthritis Rheum 32:1470, 1989
29. Lichtenstein A, Berenson J, Norman D, Chang MP, Carile A: Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74:1266, 1989
30. Dinarello CA: Anti-cytokine strategies. Eur Cytokine Netw 3:7, 1992
31. Patton JS, Peters PM, McCabe J, Crase D, Hansen S, Chen AB, Liggitt D: Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-α in rodents. J Clin Invest 80:1587, 1987
32. Mealy K, Robinson B, Millette CF, Majzoub J, Wilmore DW: The testicular effects of tumor necrosis factor. Ann Surg 211:470, 1990
33. Jäättelä M, Ilsvemäki V, Voutilainen R, Stenman U-H, Saksela E: Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal glands. Endocrinology 128:623, 1991
34. Reincke M, Heppner C, Petzke F, Allolio B, Arlt W, Mbulamberi D, Siekmann, Vollmer D, Winkelmann W, Chrousos GP: Impairment of adrenocortical function associated with increased plasma tumor necrosis factor-alpha and interleukin-6 concentrations in African trypanosiomasis. Neuroimmunomodulation 1:14, 1994
35. Pang XP, Hershman JM, Mirell CJ, Pekary AE: Impairment of hypothalamic-pituitary-thyroid function in rats treated with human recombinant tumor necrosis factor-α (cachectin). Endocrinology 125:76, 1989
36. Van der Poll T, Romijn JA, Wiersinga WM, Sauerwein HP: Tumor necrosis factor: A putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab 71:1567, 1990
37. Koike K, Masumoto N, Kasahara K, Yamaguchi M, Tasaka K, Hirota K, Miyake A, Tanizawa O: Tumor necrosis factor-α stimulates prolactin release from anterior pituitary cells: A possible involvement of intracellular calcium mobilization. Endocrinology 128:2785, 1991
38. Tracey KJ, Morgello S, Koplin B, Fahey TJ, Fox J, Aledo A, Manogue KR, Cerami A: Metabolic effects of cachectin/tumor necrosis factor are modified by the site of production. Cachectin/ tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantely acute anorexia. J Clin Invest 86:2014, 1990
39. Braegger CP, Corrigan CJ, MacDonald TT: Finger clubbing and tumour necrosis factor α. Lancet 336:759, 1990
40. Brett J, Gerlach H, Nawroth P, Steinberg S, Godman G, Stern D: Tumor necrosis factor/cachectin increases permeability of endothelial cells monolayers by a mechanism involving regulatory G proteins. J Exp Med 169:1977, 1989
41. Darling G, Fraker DL, Jensen JC, Gorschboth CM, Norton JA: Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res 50:4008, 1990
42. Feingold KR, Adi S, Staprans I, Moser AH, Neese R, Verdier JA, Doeller W, Grunfeld C: Diet affects the mechanisms by which TNF stimulates hepatic triglyceride production. Am J Physiol 259:E177, 1990
43. Plata-Salaman CR, Oomura Y, Kai Y: Tumor necrosis factor and interleukin-1-beta: Suppression of food intake by direct action in the central nervous system. Brain Res 449:106, 1988
44. Dascombe MJ, Rothwell NJ, Sagay BO, Stock MJ: Pyrogenic and thermogenic effects of interleukin-1 beta in the rat. Am J Physiol 256:E7, 1989
45. Brown SL, Smith LR, Blalock JE: Interleukin-1 and interleukin-2 enhance proopiomelanocortin gene expression in pituitary cells. J Immunol 139:3181, 1987
46. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M: Cytotoxicity of human p17 interleukin-1 for pancreatic islets of Langherans. Science 232:1545, 1986
47. Maes M, Bosmans E, Meltzer HY, Scharpé S, Suy E: Interleukin-1β: A putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 150:1189, 1993
48. Otterness IG, Golden HW, Seymour PA, Eskra JD, Daumy GO: Role of prostaglandins in behavioral changes induced by murine interleukin 1 alpha in the rat. Cytokine 3:333, 1991
49. Clinton SK, Libby P: Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 116:1292, 1992
50. Kishimoto T: The biology of interleukin-6. Blood 74:1, 1989
51. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama A: Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74:1241, 1989
52. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease Blood 74:1360, 1989
53. Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, Galanaud P, Diebold J, Emilie D: Interleukin-6 gene expression in Castleman's disease. Blood 78:2923, 1991
54. Motro B, Itin A, Sachs L, Keshet E: Pattern of interleukin-6 expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 87:3092, 1990
55. Watrous DA, Andrews BS: The metabolism and immunology of bone. Semin Arthritis Rheum 19:45, 1989